Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Update
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Update
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) was the target of a large drop in short interest in July. As of July 31st, there was short interest totalling 32,900 shares, a drop of 31.9% from the July 15th total of 48,300 shares. Based on an average trading volume of 49,200 shares, the short-interest ratio is currently 0.7 days.
奧品製藥公司(納斯達克代碼:OPNT-GET Rating)是空頭股數7月份大幅下跌的目標。截至7月31日,空頭股數共有3.29萬股,較7月15日的4.83萬股下降了31.9%。以平均成交量49,200股計算,目前短息比率為0.7天。
Analyst Ratings Changes
分析師評級發生變化
Separately, TheStreet lowered Opiant Pharmaceuticals from a "c" rating to a "d+" rating in a research report on Tuesday, May 31st.
另外,華爾街在5月31日(星期二)的一份研究報告中將Opiant PharmPharmticals的評級從“c”下調至“d+”。
Insiders Place Their Bets
內部人士下注
In other news, Director Michael Sinclair sold 7,688 shares of the company's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $12.94, for a total value of $99,482.72. Following the completion of the sale, the director now owns 41,532 shares in the company, valued at approximately $537,424.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Michael Sinclair sold 7,688 shares of the business's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $12.94, for a total transaction of $99,482.72. Following the transaction, the director now directly owns 41,532 shares in the company, valued at $537,424.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Craig A. Collard acquired 4,037 shares of the firm's stock in a transaction on Monday, June 13th. The stock was purchased at an average price of $10.94 per share, with a total value of $44,164.78. Following the purchase, the director now owns 53,822 shares in the company, valued at approximately $588,812.68. The disclosure for this purchase can be found here. Insiders have sold 23,751 shares of company stock valued at $304,412 in the last three months. 25.15% of the stock is currently owned by insiders.
在其他新聞方面,董事邁克爾·辛克萊在6月6日星期一的一筆交易中出售了7688股該公司股票。這些股票的平均價格為12.94美元,總價值為99,482.72美元。出售完成後,董事現在擁有該公司41,532股,價值約537,424.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,通過這個超級鏈接可以訪問該文件。在相關新聞中,董事邁克爾·辛克萊在一筆日期為6月6日(星期一)的交易中出售了該公司7688股股票。這些股票以12.94美元的平均價格出售,總成交金額為99,482.72美元。交易完成後,董事現在直接擁有該公司41,532股,價值537,424.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過美國證券交易委員會網站訪問該文件。此外,克雷格·A·科拉德在6月13日(星期一)的一次交易中收購了4,037股董事股票。該股是以每股10.94美元的平均價格購買的,總價值為44,164.78美元。收購完成後,董事現在擁有該公司53,822股,價值約588,812.68美元。此次收購的披露信息可在此處找到。在過去的三個月裏,內部人士已經出售了23,751股公司股票,價值304,412美元。25.15%的股份目前由內部人士持有。
Institutional Investors Weigh In On Opiant Pharmaceuticals
機構投資者看好奧品製藥
Opiant Pharmaceuticals Stock Performance
Opiant製藥公司股票表現
Shares of Opiant Pharmaceuticals stock traded up $0.90 on Friday, reaching $13.48. 31,822 shares of the company traded hands, compared to its average volume of 17,959. The company has a debt-to-equity ratio of 0.35, a current ratio of 8.72 and a quick ratio of 8.72. The firm has a market capitalization of $68.48 million, a PE ratio of -3.31 and a beta of 0.52. The company has a 50 day moving average of $11.52 and a 200 day moving average of $18.20. Opiant Pharmaceuticals has a 52 week low of $7.34 and a 52 week high of $37.71.
週五,Opiant PharmPharmticals的股價上漲了0.9美元,達到13.48美元。該公司31,822股易手,而其平均成交量為17,959股。該公司的債務權益比為0.35,流動比率為8.72,速動比率為8.72。該公司市值為6848萬美元,市盈率為-3.31,貝塔係數為0.52。該公司的50日移動均線切入位在11.52美元,200日移動均線切入位在18.20美元。Opiant PharmPharmticals的52周低點為7.34美元,52周高點為37.71美元。
Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last released its earnings results on Tuesday, May 10th. The technology company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($1.68). Opiant Pharmaceuticals had a negative return on equity of 46.15% and a negative net margin of 51.18%. The firm had revenue of $4.47 million during the quarter, compared to analysts' expectations of $7.13 million. During the same period in the prior year, the business earned ($0.66) earnings per share. Equities analysts forecast that Opiant Pharmaceuticals will post -6.21 earnings per share for the current year.
奧品製藥(納斯達克代碼:OPNT-GET Rating)最近一次公佈財報是在5月10日(星期二)。這家科技公司公佈的季度每股收益(EPS)為2.43美元,低於分析師普遍預期的0.75美元和1.68美元。Opiant製藥公司的淨資產回報率為負46.15%,淨利潤率為負51.18%。該公司本季度營收為447萬美元,高於分析師預期的713萬美元。去年同期,該業務實現每股收益(0.66美元)。股票分析師預測,Opiant PharmPharmticals本年度每股收益將達到6.21美元。
About Opiant Pharmaceuticals
關於Opiant製藥公司
(Get Rating)
(獲取評級)
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Opiant PharmPharmticals,Inc.是一家專業製藥公司,開發治療成癮和藥物過量的藥物。該公司提供納爾坎鼻噴劑,一種逆轉阿片類藥物過量的治療方法。其候選產品包括治療阿片類藥物過量逆轉、酒精使用障礙、急性大麻類藥物過量和阿片類藥物使用障礙的藥物。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於Opiant製藥的研究報告(OPNT)
- 值得關注的兩場重要的零售股大戰
- MarketBeat:回顧中的一週2012-8-8
- 什麼是WallStreetBets,他們的目標是什麼股票?
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Opiant PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Opiant製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。